Jan 16 (Reuters) - Mylan has agreed to pay $73.5 million to settle a class action lawsuit by drug wholesalers accusing the drugmaker of scheming to overcharge them for EpiPen allergy treatment ...
Injectable glucagon has been the primary treatment for ... of rescue therapy for healthcare practitioners, likening it to Mylan’s $1 billion EpiPen product for severe allergic reactions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback